Ibrance is an anti-cancer drug owned by Pfizer. It contains the active ingredient palbociclib and is available in capsule and oral dosage forms. Ibrance was first authorised for market use on 03 February, 2015. It has a total of 6 drug patents, out of which 3 have expired.
The generic version of Ibrance is expected to be released after 19 August, 2036. This release date considers the expiry date of the last patent, US11065250 titled 'Solid dosage forms of palbociclib', which expires on 19 August, 2036.
Ibrance, or palbociclib, is primarily used for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. It is often used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men, or with fulvestrant in patients with disease progression after endocrine therapy.
Ibrance has a collection of 6 patents. Of these, the last patent to expire will be patent US11065250 - 'Solid dosage forms of palbociclib', which is due on 19 August, 2036. This is the patent that holds the key to Ibrance generic release. Below are the details of the patents: